Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel Free ENLV Stock Alerts

Enlivex Therapeutics (ENLV) Competitors

Enlivex Therapeutics logo
$0.81 +0.08 (+10.92%)
Closing price 09/18/2026 03:59 PM Eastern
Extended Trading
$0.81 0.00 (-0.07%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ENLV vs. XLO, EXOZ, IMA, ELTX, and APLM

Should you buy Enlivex Therapeutics stock or one of its competitors? Enlivex Therapeutics's main competitors and comparable companies include Xilio Therapeutics (XLO), eXoZymes (EXOZ), ImageneBio (IMA), Elicio Therapeutics (ELTX), and Apollomics (APLM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enlivex Therapeutics compare to Xilio Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Enlivex Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Enlivex Therapeutics' return on equity of 248.08% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A 248.08% 206.39%
Xilio Therapeutics -34.06%-71.99%-20.43%

Enlivex Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

In the previous week, Xilio Therapeutics had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 1 mentions for Xilio Therapeutics and 0 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company Overall Sentiment
Enlivex Therapeutics Neutral
Xilio Therapeutics Neutral

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Enlivex Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A
Xilio Therapeutics$43.77M1.37-$35.04M-$1.64N/A

Enlivex Therapeutics presently has a consensus price target of $247.50, suggesting a potential upside of 30,584.35%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Xilio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Enlivex Therapeutics beats Xilio Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to eXoZymes?

Enlivex Therapeutics (NASDAQ:ENLV) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Enlivex Therapeutics has higher earnings, but lower revenue than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A
eXoZymes$70K852.43-$9.16M-$1.19N/A

Enlivex Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, indicating that its share price is 214% more volatile than the broader market.

Enlivex Therapeutics currently has a consensus target price of $247.50, suggesting a potential upside of 30,584.35%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than eXoZymes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat eXoZymes' return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A 248.08% 206.39%
eXoZymes N/A -292.15%-158.66%

In the previous week, Enlivex Therapeutics' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company Overall Sentiment
Enlivex Therapeutics Neutral
eXoZymes Neutral

Summary

Enlivex Therapeutics beats eXoZymes on 9 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to ImageneBio?

Enlivex Therapeutics (NASDAQ:ENLV) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Enlivex Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Enlivex Therapeutics has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A
ImageneBio$800K69.38-$45.35M-$4.58N/A

Enlivex Therapeutics' return on equity of 248.08% beat ImageneBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A 248.08% 206.39%
ImageneBio N/A -38.99%-34.84%

Enlivex Therapeutics currently has a consensus target price of $247.50, suggesting a potential upside of 30,584.35%. ImageneBio has a consensus target price of $29.00, suggesting a potential upside of 493.05%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Enlivex Therapeutics is more favorable than ImageneBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
ImageneBio
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.20

In the previous week, ImageneBio had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for ImageneBio and 0 mentions for Enlivex Therapeutics. ImageneBio's average media sentiment score of 0.51 beat Enlivex Therapeutics' score of 0.00 indicating that ImageneBio is being referred to more favorably in the news media.

Company Overall Sentiment
Enlivex Therapeutics Neutral
ImageneBio Positive

Summary

Enlivex Therapeutics beats ImageneBio on 8 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elicio TherapeuticsN/AN/A-$39.57M-$2.17N/A
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A

Elicio Therapeutics currently has a consensus price target of $19.75, suggesting a potential upside of 944.97%. Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 30,584.35%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Enlivex Therapeutics' return on equity of 248.08% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Elicio TherapeuticsN/A -1,266.43% -139.94%
Enlivex Therapeutics N/A 248.08%206.39%

In the previous week, Elicio Therapeutics had 2 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 2 mentions for Elicio Therapeutics and 0 mentions for Enlivex Therapeutics. Elicio Therapeutics' average media sentiment score of 0.89 beat Enlivex Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Elicio Therapeutics Positive
Enlivex Therapeutics Neutral

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Elicio Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Elicio Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 30,584.35%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Apollomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Enlivex Therapeutics has lower revenue, but higher earnings than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50M5.85-$10.94MN/AN/A
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A

In the previous week, Apollomics had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for Enlivex Therapeutics. Apollomics' average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score.

Company Overall Sentiment
Apollomics Neutral
Enlivex Therapeutics Neutral

Enlivex Therapeutics' return on equity of 248.08% beat Apollomics' return on equity.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Enlivex Therapeutics N/A 248.08%206.39%

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Enlivex Therapeutics beats Apollomics on 8 of the 12 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

Export
MetricEnlivex TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$14.10M$3.89B$7.24B$13.19B
Dividend YieldN/A3.64%2.57%12.81%
P/E Ratio-0.1014.23275.4925.40
Price / SalesN/A1,419.61646.0189.45
Price / CashN/A108.9076.2551.42
Price / Book0.0115.4510.466.33
Net Income$1.24B-$22.86M$3.49B$358.33M
7 Day Performance-15.94%-1.21%0.59%1.12%
1 Month Performance-46.23%-3.29%-1.74%-2.39%
1 Year Performance-94.85%37.74%18.13%5.35%

Enlivex Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENLV
Enlivex Therapeutics
2.2686 of 5 stars		$0.81
+10.9%		$247.50
+30,584.4%		-94.9%$14.10MN/AN/A34
XLO
Xilio Therapeutics
0.0431 of 5 stars		$9.03
+1.1%		N/A-16.4%$58.76M$43.77MN/A70
EXOZ
eXoZymes
0.5258 of 5 stars		$6.57
+4.6%		N/A-55.6%$58.29M$70KN/A29
IMA
ImageneBio
3.097 of 5 stars		$4.92
-1.6%		$29.00
+489.4%		-40.7%$56.76M$800KN/A70
ELTX
Elicio Therapeutics
2.4296 of 5 stars		$1.99
-0.5%		$19.75
+892.5%		-83.5%$52.56MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel